Arkolith/Insider Trading/ARQT/Form 4

Watanabe Todd

See Remarks, DirectorArcutis Biotherapeutics, Inc. (ARQT) · full profile →Form 4 · filed Mar 3, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$941K
Net Open-Market Flow
-$941K
Transactions
4
3 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Sell(S)1K$25.91$28K786K
Mar 2, 2026Sell(S)36K$25.16$913K787K
Feb 27, 2026Grant(A)102K—$0823K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 27, 2026Grant(A)266K—$0266K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-014327) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML